No abstract available
MeSH terms
-
Animals
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / pharmacology
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
CD40 Antigens / antagonists & inhibitors
-
CTLA-4 Antigen / antagonists & inhibitors
-
CTLA-4 Antigen / immunology
-
Cancer Vaccines / administration & dosage
-
Cancer Vaccines / immunology
-
Cancer Vaccines / therapeutic use
-
Child
-
Clinical Trials as Topic
-
Endpoint Determination
-
Epigenesis, Genetic / drug effects
-
Humans
-
Immunotherapy* / trends
-
Ipilimumab
-
Melanoma / drug therapy
-
Melanoma / immunology
-
Mice
-
Neoplasms / drug therapy*
-
Neoplasms / immunology*
-
Neoplasms / therapy
-
Nivolumab
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
-
Survivors
-
T-Lymphocytes / drug effects
-
T-Lymphocytes / immunology
Substances
-
Antibodies, Monoclonal
-
CD40 Antigens
-
CTLA-4 Antigen
-
Cancer Vaccines
-
Ipilimumab
-
Nivolumab